Every year, specialized companies conduct international market research on developments in alternative methods to animal testing. This information is essential for manufacturers and industrial policy makers. The data changes rapidly, and it is necessary to update these prospective studies at regular intervals. This is exactly what the company BYR (“Build Your Reports”) did in 2026. Here we provide a summary of the report’s approximately 250 pages. The methodology is detailed at the end of the article.
Overview and Market Forecasts
The global market for alternative methods to animal testing is undergoing a profound transformation. Pharmaceutical, biotechnology, cosmetics, and chemical companies, as well as research organizations, are increasingly adopting these approaches to evaluate the safety, efficacy, and toxicity of products. This market encompasses in vitro testing, organoids, microphysiological organ-on-a-chip systems, computational modeling, and methods based on artificial intelligence—collectively referred to as “New Approach Methodologies” (NAM, “New Approach Methodologies”).
The global market was valued at 2,802 million USD in 2025 and is projected to reach 6,166 million USD in 2033, representing a compound annual growth rate (CAGR) of 10.4% over the 2025–2033 period.
| Global Market | 2020 | 2025 | 2033 | CAGR 2025–2033 |
| Value (M USD) | 1,759 | 2,802 | 6,166 | 10.4% |
Market Segmentation
By testing approach/method
The market is segmented into five major categories of methods, whose growth varies significantly depending on the level of technological maturity and regulatory adoption.
“Human-relevant in vitro methods” constitute the dominant segment, growing from 1,497 M USD in 2025 to 3,370 M USD in 2033 (CAGR of 10.7%); this segment includes 2D cell-based assays (502 → 922 M USD; CAGR 7.9%, the most mature sub-segment but with the most moderate growth), 3D spheroid models ($309 million → $756 million; 11.8% CAGR), reconstructed human tissues ($241 million → $533 million; 10.4% CAGR), organoids (182 → 486 M USD; CAGR 13.1%), and organ-on-a-chip and microphysiological systems, which are growing the fastest within the entire in vitro segment (159 → 466 M USD; CAGR 14.4%), driven by technological advances and the pharmaceutical industry’s growing interest in more physiologically representative models.
The “in silico/computational methods” segment is also growing strongly, from 700 M USD to 1,622 M USD (CAGR of 11.1%, the second-highest after organs-on-a-chip), driven by the rise of artificial intelligence. It includes QSAR models (211 → 447 M USD; CAGR of 9.8%), read-across approaches (181 → 419 M USD; CAGR of 11.1%), PBK/PBPK modeling (128 → 312 M USD; CAGR 11.8%), and predictive models based on AI and machine learning, which constitute the sub-segment with the highest CAGR in the entire market (121 → 335 M USD; CAGR 13.5%).
“In chemico/cell-free methods” grew from 267 M USD to 545 M USD (CAGR of 9.3%), driven in particular by molecular interaction and reactivity assays ($233 million → $481 million; 9.5% CAGR).
“Human-derived ex vivo methods” grew from $216 million to $411 million (CAGR of 8.4%), driven by freshly isolated human tissue models ($111 million → $207 million; CAGR 8.1%) and tissue models derived from surgery or biopsy ($79 million → $160 million; CAGR 9.2%).
Finally, other non-animal methods grew from $123 million to $216 million (CAGR of 7.4%), representing the most moderate growth rate among the five major categories.
By end user
Pharmaceutical and biotechnology companies are by far the largest end-user segment, representing a market that will grow from 1,334 M USD in 2025 to 3,090 M USD in 2033, with the highest CAGR among end users (11.1%)—reflecting intensified R&D activities and growing regulatory pressure in favor of NAMs in drug development. Contract research organizations and independent testing laboratories are also experiencing sustained growth (330 → 737 M USD; CAGR of 10.6%), driven by the increasing outsourcing of testing activities.
Chemical and consumer goods companies grew from 305 M USD to 673 M USD (CAGR of 10.4%), while the cosmetics and personal care sector grew from $355 million to $733 million (CAGR of 9.5%), a growth trend constrained by strict regulatory restrictions on animal testing for cosmetic products in several jurisdictions. Academic and research institutions grew from $197 million to $400 million (CAGR of 9.2%), public and regulatory laboratories from $94 million to $186 million (CAGR of 9%), and agri-food companies—the smallest segment—from $125 million to $234 million (CAGR of 8.2%).
By geographic region
North America remains the world’s leading region, growing from 1,129 M USD in 2025 to 2,492 M USD in 2033 (CAGR of 10.4%).
From a regulatory standpoint, the environment is becoming increasingly favorable to alternative methods in the United States. The Environmental Protection Agency (EPA) actively promotes NAMs under the Toxic Substances Control Act (TSCA), including human cell-based models and computational methods for chemical safety assessment. In 2026, the EPA expanded its “NAM” framework and reaffirmed its goal of phasing out mammalian testing by 2035. The Food and Drug Administration (FDA) also encourages human-relevant alternatives in pharmaceutical development and, in March 2026, published a project of guidelines specifying the validation criteria for NAMs used in drug development dossiers, emphasizing the context of use, human biological relevance, and technical characterization.
Europe remains in second place, with revenue rising from 838 M USD to 1,789 M USD (CAGR of 9.9%).
Germany dominates the European market (183 → 429 M USD; 11.2% CAGR, the highest on the continent), followed by the United Kingdom (152 → 342 M USD; CAGR of 10.7%) and France, with growth from 122 M USD in 2025 to 267 M USD in 2033, representing a CAGR of 10.2%; the French market is expected to exceed 150 M USD in 2027 and 200 M USD in 2030.
Under the European Union’s REACH Regulation, testing on vertebrate animals is permitted only as a last resort, when no adequate alternative information is available; companies must first consider existing data, read-across approaches, computational methods, and data sharing. The European Cosmetics Regulation also imposes strict restrictions on animal testing for cosmetic products and ingredients, although its interaction with REACH can create regulatory complexities for substances with broader industrial uses. The European Chemicals Agency (ECHA) continues to develop and promote non-animal approaches: its 2026 report on alternatives to animal testing reflects the ongoing regulatory assessment, and in 2026, ECHA launched a collaborative platform on alternatives to animal testing to strengthen cooperation among regulators, industry, and research organizations.
The Asia-Pacific region is also experiencing rapid growth, with a CAGR of 11% (677 → 1,565 M USD), followed by Latin America (CAGR of 9.4%) and the Middle East/Africa (CAGR of 8.8%).
Key Factors and Outlook
Market growth is driven by increased regulatory support for non-animal testing, growing ethical concerns regarding animal testing, rising demand for methods relevant to humans, advances in organ-on-a-chip systems, the intensification of pharmaceutical and biotechnology R&D activities, and the growing adoption of artificial intelligence and computational modeling. The main barriers identified are the high cost of advanced alternative technologies and the still-limited standardization and validation of certain methods.
In the longer term, investment, industry collaboration, and regulatory modernization are expected to create opportunities for technology developers, contract research organizations, pharmaceutical and biotechnology companies, and specialized laboratories—particularly around integrated testing platforms that combine human-derived models, computational approaches, automation, and data analysis. As regulatory frameworks solidify and standards of evidence harmonize, alternative non-animal methods are expected to become an increasingly central component of pharmaceutical development, toxicology, chemical safety, and life sciences research.
Study Methodology
The scope of the study covers commercially available non-animal testing technologies and services (products, platforms, assays, models, software, consumables, and services) used by researchers for research, safety assessment, toxicology, product development, and related testing activities. Revenue related to conventional animal testing is excluded from the scope.
The analysis covers the period 2020–2033, with 2025 as the base year, and all figures are expressed in millions of USD.
Qualitative Component
The qualitative component is based on: an analysis of regulatory, scientific, technological, and adoption trends specific to non-animal methods; mapping of companies, products, platforms, assays, software, and testing services within the defined market scope; an assessment of progress in scientific validation, user requirements, competitive positioning, partnerships, product launches, and marketing activities; and the identification of growth drivers, barriers, opportunities, and challenges in the market, regulatory trends, and R&D demand.
Quantitative Component
The quantitative component is based on a model of historical and projected market revenues for 2020–2033 and on a breakdown of revenues by company, testing method, user, region, and country. The estimate combines a top-down approach—allocating consolidated global revenue using validated regional, technological, and sector-specific indicators—and a bottom-up approach—aggregating revenue from identified companies, products, platforms, and services. The two approaches are reconciled through cross-checking of data, ensuring that each market dimension (method, end user, region, country) adds up to the total.
Data sources
The research draws on company websites, annual reports, investor materials, product and service documentation, regulatory filings, government and institutional sources, trade associations, scientific journals, white papers, and conference materials, among others. It helps identify the market structure, the technological landscape, supplier participation, product and service portfolios, user adoption, and regulatory trends by region.
Source: 2026, “Global Non-Animal Alternative Testing—Market Research Report, 2020–2033.”
